Q2 2022
Released Nov 5, 2021, before the open
10-Q filed Nov 5, 2021, 36 days after period end · 0001764013-21-000119
Q2 2022 · 10-Q
Revenue—
Net Income-$37.70M-$37.70M no prior Q2 2021 on fileN/M vs Q1 2022
EPS Diluted-$0.35-$0.35 no prior Q2 2021 on fileN/M vs Q1 2022
Operating Cash Flowderived-$20,047,000—
Free Cash Flowderived-$20,091,000—
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2018 |
|---|---|---|
| Net Income | -$37.70M | -$6.35M |
| EPS Diluted | -$0.35 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR